

1 Subject heading: Dementia

## 2 **Are severe infections a gateway to dementia?**

3 Mika Kivimäki

4 Brain Sciences, University College London, London, UK

5 m.kivimaki@ucl.ac.uk

6 Keenan A. Walker

7 Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, MD, USA

8

### 9 **Abstract**

10 A new study in *Nature Aging* on electronic health records from 1.7 million New Zealanders reveals  
11 that most patients with dementia have a history of hospital-treated infection. In a dementia-free  
12 population, individuals with a severe infection were at threefold higher risk of dementia even 25  
13 years later.

### 14 **Main**

15 While individuals with severe infections experience a higher likelihood of developing dementia later  
16 in life, the underlying reasons for this association remain a subject of debate. An early hypothesis  
17 suggested that dementia may be an infectious disease caused by a pathogen. This ‘germ’ hypothesis  
18 was supported by observations that Alzheimer’s disease is more common in groups of individuals  
19 who are in contact with dementia patients, such as spouses and neurosurgeons.<sup>1</sup> More recently,  
20 researchers have proposed that infections may represent a risk factor for dementia (the ‘infectious  
21 hypothesis’) or that infections accelerate the progression of dementia pathology already underway  
22 (the ‘infectious-accelerant theory’).<sup>2</sup>

23 However, there are also more skeptical views. According to them, the association may be an artefact  
24 arising from reverse causation where increased vulnerability to severe infections is the consequence  
25 of preclinical dementia rather than a cause. A further possibility is that the link is driven by a third  
26 factor, such as shared genetics between susceptibility to infections and dementia, accelerated  
27 biological ageing contributing to both age-related immune-senescence and neurodegeneration, or  
28 an underlying condition both compromises immune function and increases dementia risk (e.g.  
29 diabetes, cardiovascular disease or depression). If these scenarios were true and accounted for the  
30 entirety of the observed infection-dementia relationship, the link between infections and dementia  
31 would be spurious.

32 In this issue of *Nature Aging*, Richmond-Rakerd *et al.* investigate associations of hospital-treated  
33 infections with subsequent dementia in a nationwide study from New Zealand.<sup>3</sup> Using electronic

34 records from national health registries, the authors identified individuals born between 1929 and  
35 1968 and followed them from 1989 to 2019. The study population included a total of 1.7 million  
36 participants aged 21 to 60 years at baseline. Dates and diagnoses of infections were obtained from  
37 hospital admission records. For dementia ascertainment, data from mortality and pharmaceutical  
38 registries, in addition to hospitalisations, were used. In this extensive study with a 30-year follow-up,  
39 more than 465,000 individuals experienced infections and 37,000 developed dementia. The median  
40 age at the first infection diagnosis was 9.3 years before the median age of dementia diagnosis. The  
41 authors found that among individuals diagnosed with dementia, 66% had a history of infections,  
42 compared to 26% in individuals without dementia. Furthermore, those with an infection diagnosis  
43 had a 2.9-fold higher risk of subsequent dementia (95% CI 2.7–3.2) compared to those without an  
44 infection diagnosis. These findings are consistent with those reported from other large-scale cohort  
45 studies from Europe and the US.<sup>4</sup>

46 Furthermore, Richmond-Rakerd et al. conducted a series of supplementary analyses, providing  
47 valuable insights that should be interpreted in light of existing evidence.<sup>3</sup> Firstly, Alzheimer’s disease  
48 pathology typically manifests 1 to 2 decades before clinical symptom onset, posing challenges in  
49 determining whether increased susceptibility to infections contributes to or reflects dementia  
50 pathogenesis. Previous analyses from a multicohort study involving 200,000 participants have shown  
51 that the association between hospital-treated infections and dementia persists even when restricted  
52 to cases where dementia develops more than 10 years after the infection.<sup>5</sup> However, this does not  
53 entirely rule out the possibility of reverse causation. In their study, Richmond-Rakerd and colleagues  
54 addressed this limitation by stratifying the 30-year follow-up period into 5-year intervals.<sup>3</sup> Their  
55 findings indicate that the heightened risk remains consistent across all follow-up intervals, ranging  
56 from 1-5 years (hazard ratio 2.5, 95% CI 2.3–2.6) to 25-30 years (hazard ratio 3.6, 95% CI 3.1–4.2).  
57 This suggests that reverse causation is an unlikely explanation for the observed link.

58 Secondly, Richmond-Rakerd et al. conducted several analyses to mitigate the influence of third  
59 factors.<sup>3</sup> These included adjusting for pre-existing physical diseases and mental disorders through  
60 multivariable models, such as diabetes, stroke, coronary heart disease, gout, COPD, cancer,  
61 traumatic brain injury, mood and neurotic disorders, substance use disorders, and psychotic  
62 disorders. Additionally, the authors stratified the analyses by birth year to assess whether the  
63 observed link persists at younger ages, where age-related changes in the immune system, such as  
64 up-regulation of pro-inflammatory signalling and reductions in naïve lymphocytes, antibody  
65 effectiveness, and phagocytic capacity, are not yet prevalent, and chronic conditions compromising  
66 the immune system are rare. The main finding remained consistent across all these analyses.  
67 Although each of these analyses provided additional support for infection’s role as a dementia risk  
68 factor, the potential explanatory effect of genetic variants jointly associated infection vulnerability  
69 and dementia risk, as well as other factors, such as advanced immune age, could not be ruled out.

70 Thirdly, much research has centred on specific infections or sets of pathogens, with a particular  
71 emphasis on viruses known to cross the blood-brain barrier—a critical structure shielding the brain  
72 from harmful substances in the bloodstream. These neurotropic pathogens include, for instance,  
73 herpes simplex and human immunodeficiency viruses, both implicated in increased dementia risk.<sup>2</sup>  
74 However, recent epidemiological studies covering a wide range of infections have revealed that  
75 hospitalisation for nearly any infection is associated with heightened dementia risk, showing little  
76 specificity for the type of infection and including both central nervous system (CNS) and extra-CNS

77 infections.<sup>5-8</sup> This observation was corroborated by Richmond-Rakerd et al. They found no significant  
78 differences in effect estimates between viral, bacterial, parasitic, or other infections.<sup>3</sup> Taken  
79 together, these findings indicate that not only brain infections, but also infections that occur outside  
80 the CNS, are linked to an elevated risk of dementia. Therefore, rather than pursuing a specific major  
81 dementia-causing pathogen, research should prioritize understanding the mechanisms shared by  
82 severe infections that may increase dementia risk. It is worth noting that mild infections are not  
83 consistently associated with dementia risk.<sup>6</sup>

84 How do infections increase the risk of dementia? One hypothesis suggests that the underlying  
85 mechanisms involve the brain's response to neurotrophic pathogens. In this scenario, infectious  
86 agents penetrate the CNS, activate the brain's immune response in a manner which promotes  
87 sustained neuroinflammation, resulting in downstream neurodegenerative damage (e.g., excessive  
88 synaptic pruning, neuronal apoptosis; *Figure 1*).<sup>4,9</sup> However, the findings presented by Richmond-  
89 Rakerd et al. and the findings from a long list of previous studies suggest that pathogens need not  
90 enter the CNS to have deleterious effect on brain function. Acute infections that occur outside the  
91 CNS typically trigger an innate immune response characterized by the expression of immune  
92 signalling molecules, such as cytokines and chemokines, at or near the site of infection. Although  
93 cytokines and chemokines are produced outside the CNS in this context, these molecules can exert  
94 an effect within the CNS through a number of conduits, including via the blood-brain barrier (which  
95 becomes more permeability during acute infections), through the meningeal lymphatic system, via  
96 the choroid plexus, and as an indirect consequence of brain endothelial cell activation. Through each  
97 of these components of the neuro-immune axis (*Figure 1*), severe peripheral infections may cause an  
98 influx of inflammatory mediators and immune cells into the brain parenchyma, contributing to  
99 neuroinflammation. A third pathway could involve mechanisms where peripheral immune challenge  
100 leads to the suppression of perivascular flow of cerebrospinal fluid (i.e., glymphatic drainage),  
101 impairing the clearance of potentially neurotoxic waste products from the CNS to the peripheral  
102 immune system. However, human evidence for this mechanism is limited. Additionally,  
103 epidemiological studies have suggested that vascular mechanisms may play a role, as the association  
104 of severe infections is stronger for vascular dementia than for Alzheimer's disease<sup>5</sup>—a finding also  
105 replicated in the study by Richmond-Rakerd *et al.*<sup>3</sup> Specific mechanistic explanations for the link  
106 between infection and vascular-mediated cognitive decline include endothelial dysfunction and  
107 thrombosis secondary to acute inflammation, infection-related platelet aggregation, and accelerated  
108 accumulation atherogenesis.<sup>10</sup>

109 Richmond-Rakerd *et al.* conclude their paper by suggesting that effective prevention of infections  
110 might reduce the burden of dementia.<sup>3</sup> Although there is no consistent evidence from larger  
111 randomized controlled trials to demonstrate that targeting infection and inflammation would be  
112 effective in reducing cognitive impairment or the risk and progression of dementia,<sup>11</sup> epidemiological  
113 studies suggest that vaccination against certain infections (e.g., varicella zoster virus) may reduce  
114 dementia risk.<sup>12</sup> Before specific prevention or treatment recommendations can be made, more  
115 work is needed to understand the unifying mechanisms that jointly link multiple infection types to  
116 enhanced dementia risk. Although systemic inflammation has been proposed as a potential unifying  
117 mechanism, anti-inflammatory trials on non-steroidal anti-inflammatory medications, such as  
118 naproxen and celecoxib,<sup>13</sup> as well as minocycline, a tetracycline antibiotic<sup>14</sup> have reported null  
119 findings. To the degree that systemic inflammation is a common risk factor for dementia onset  
120 among those with an infection history, more targeted approaches to immunomodulation of specific

121 implicated pathways (e.g. cGAS-STING) may prove more efficacious than broad immunosuppression.  
122 Big data in combination with modern genetic and causal inference methods have already shed some  
123 light on this issue. For example, recent Mendelian Randomization analyses suggest that specific  
124 immune cell types and proteins associated with autoimmunity might be a modifiable component in  
125 dementia-causing diseases.<sup>15</sup> Yet, to date, this hypothesis has not been tested in clinical trials.

## 126 References

- 127 1. Abbott, A. Could an infection trigger Alzheimer's disease? *Nature* **587**, 22-25 (2020).
- 128 2. Itzhaki, R.F., *et al.* Microbes and Alzheimer's Disease. *J Alzheimers Dis* **51**, 979-984 (2016).
- 129 3. Richmond-Rakerd, L.S., *et al.* Associations of hospital-treated infections with subsequent  
130 dementia: Nationwide 30-year analysis. *Nature Aging* **xx**, yyy-yyy (2024).
- 131 4. Walker, K.A., *et al.* The role of peripheral inflammatory insults in Alzheimer's disease: a  
132 review and research roadmap. *Mol Neurodegener* **18**, 37 (2023).
- 133 5. Sipilä, P.N., *et al.* Hospital-treated infectious diseases and the risk of dementia: a large,  
134 multicohort, observational study with a replication cohort. *Lancet Infectious Diseases* **16**,  
135 1686-1695 (2021).
- 136 6. Muzambi, R., *et al.* Assessment of common infections and incident dementia using UK  
137 primary and secondary care data: a historical cohort study. *Lancet Healthy Longev* **2**, e426-  
138 e435 (2021).
- 139 7. Mawanda, F., Wallace, R.B., McCoy, K. & Abrams, T.E. Systemic and localized extra-central  
140 nervous system bacterial infections and the risk of dementia among US veterans: A  
141 retrospective cohort study. *Alzheimers Dement (Amst)* **4**, 109-117 (2016).
- 142 8. Bohn, B., *et al.* Incidence of dementia following hospitalization with infection among adults  
143 in the Atherosclerosis Risk in Communities (ARIC) Study Cohort. *JAMA Netw Open* **6**,  
144 e2250126 (2023).
- 145 9. Chen, X. & Holtzman, D.M. Emerging roles of innate and adaptive immunity in Alzheimer's  
146 disease. *Immunity* **55**, 2236-2254 (2022).
- 147 10. Elkind, M.S.V., Boehme, A.K., Smith, C.J., Meisel, A. & Buckwalter, M.S. Infection as a stroke  
148 risk factor and determinant of outcome after stroke. *Stroke* **51**, 3156-3168 (2020).
- 149 11. Yu, J.T., *et al.* Evidence-based prevention of Alzheimer's disease: systematic review and  
150 meta-analysis of 243 observational prospective studies and 153 randomised controlled trials.  
151 *J Neurol Neurosurg Psychiatry* **91**, 1201-1209 (2020).
- 152 12. Eyting, M., Xie, M., Hess, S. & Geldsetzer, P. Causal evidence that herpes zoster vaccination  
153 prevents a proportion of dementia cases. *medRxiv* (2023).
- 154 13. Meyer, P.F., *et al.* INTREPAD: A randomized trial of naproxen to slow progress of  
155 presymptomatic Alzheimer disease. *Neurology* **92**, e2070-e2080 (2019).
- 156 14. Howard, R., *et al.* Minocycline at 2 different dosages vs placebo for patients with mild  
157 Alzheimer Disease: A randomized clinical trial. *JAMA Neurol* **77**, 164-174 (2020).
- 158 15. Lindbohm, J.V., *et al.* Immune system-wide Mendelian randomization and triangulation  
159 analyses support autoimmunity as a modifiable component in dementia-causing diseases.  
160 *Nature Aging* **2**, 956-972 (2022).

161

162

## 163 Acknowledgements

164 M Kivimäki was supported by Wellcome Trust (221854/Z/20/Z), National Institute on Aging (NIA)  
165 (R01AG056477), Medical Research Council (MR/R024227/1, MR/Y014154/1) and Academy of  
166 Finland (350426). KA Walker was supported by the NIA's Intramural Research Program. This work  
167 was supported by the Wellcome Trust Collaborative Award in Science and the NIA Intramural  
168 Research Program.

## 169 Competing interests

170 The author declares no competing interests.

171

## 172 Figure legend

### 173 Fig 1 | Mechanisms linking infections and increased risk of dementia

174 **a,b**, Richmond-Rakerd et al. observed that a broad spectrum of severe infections, including both CNS  
175 and extra-CNS infections, was linked to an increased risk of dementia. This confirms prior  
176 epidemiological findings that have shown limited specificity regarding the type of infections  
177 associated with dementia risk (**a**). Thus, it is plausible that peripheral immune responses which are  
178 common across various severe infections (**b**) may contribute to the heightened risk of dementia.  
179 **c,d,e**, Richmond-Rakerd et al. also found a link between infections and all the examined subtypes of  
180 dementia, with a stronger association observed for vascular dementia compared to Alzheimer's  
181 disease. This is consistent with general explanations for increased dementia risk in relation to  
182 infections, such as blood-brain barrier dysfunction (**c**) and suppression of glymphatic drainage (**d**), as  
183 well as evidence that emphasises vascular mechanisms (**e**). *Abbreviations*: C. pneumoniae,  
184 Chlamydia pneumoniae; CNS, central nervous system; CMV, cytomegalovirus; DAMPs, damage-  
185 associated molecular patterns; EBV, Epstein-Barr virus; H. pylori, Helicobacter pylori; HSV, herpes  
186 simplex virus; IL, interleukin; PAMPs, pathogen-associated molecular patterns; SASP, Senescence-  
187 Associated Secretory Phenotype; TNF, tumour necrosis factor; VZV, varicella zoster virus.

## Infection Exposure

## Peripheral Immune Response

## Effect on Central Nervous System

Acute

**a**

Acute infections  
(e.g. pneumonia, septicaemia, surgical site infection, urinary track infection, cellulitis, COVID-19)

Chronic infections  
(e.g. HSV-1/2, VZV, EBV, *C. pneumoniae*, *H. pylori*, CMV, periodontal disease)

**b**

↑PAMPs      ↑DAMPs  
↓                      ↓  
Innate immune activation  
↓  
Acute inflammatory response

↑ Epigenetic reprogramming of myeloid cells

↑ Chronic low-grade cytokine expression (TNF, IL6, IL1 $\beta$ , IL18)

↑ Immune cell ageing

↑ SASP expression from senescent cells

**c**

Blood-brain barrier dysfunction  
→ Priming and activation of microglia and astrocytes  
→ Neuroinflammation, ↓ microglial phagocytosis, ↑ synaptic pruning and neuronal death

**d**

Suppression of glymphatic drainage  
→ Reduced clearance of  $\beta$ -amyloid and CNS neurotoxins

**e**

Vascular dysfunction  
→ Cerebral microbleeds, microinfarct, lacunar infarcts, stroke

Chronic